FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387135845> ?p ?o ?g. }

• W4387135845 abstract "<h3>Introduction/Background</h3> Neoadjuvant chemotherapy (NACT) followed by surgery has been shown to be an alternative treatment in patients with advanced ovarian cancer who are unlikely to achieve optimal cytoreduction with primary surgery. Successful stratification tools have been created to determine cytoreduction prognosis. The Chemotherapy Response Index is intended to be one of them. <h3>Objective</h3> To evaluate the impact on overall survival at 3 and 5 years of patients treated with NACT according to the Chemotherapy Response S core (CRS). <h3>Methodology</h3> Retrospective analysis of a longitudinal cohort study. All patients diagnosed with FIGO stage IIIC ovarian cancer who received NACT followed by surgery as treatment during the study period 2017–2022 were included. All patients received between 4–6 cycles of chemotherapy, carbo-taxol schedule followed by surgery. CRS score was analyzed in all of them. A CRS score 1 and 2 indicated partial chemotherapy response while CRS score 3 indicated very good response to chemotherapy. 3- and 5-year survival was analyzed according to the CRS score. <h3>Results</h3> A total of 57 patients met the inclusion criteria, representing 40.7% of all stage IIIC ovarian cancers in that period. The mean age of the patients was 62 years, and 75.4% were menopausal. The most frequent tumor type was serous carcinoma (93%). A CRS 1–2 was present in 80.7% (n= 46). Clinicopathological characteristics were compared between the CRS 1–2 and CRS 3 groups and no statistically significant differences were found between the two groups. Survival of patients at 3 and 5 years in the CRS 3 group was 100%, while in the CRS 1–2 group it was 68.9% and 53.3% respectively, these differences being statistically significant (Long Rack of 0.04 and 0.009). <h3>Conclusion</h3> In our study, presenting a CRS 3 after treatment with NACT followed by surgery is a good prognostic factor with a 3- and 5-year survival of 100%. <h3>Disclosures</h3> No disclosures" @default.
• W4387135845 created "2023-09-29" @default.
• W4387135845 creator A5010610972 @default.
• W4387135845 creator A5034099505 @default.
• W4387135845 creator A5038749148 @default.
• W4387135845 creator A5048878911 @default.
• W4387135845 creator A5092960937 @default.
• W4387135845 creator A5092960938 @default.
• W4387135845 creator A5092960939 @default.
• W4387135845 date "2023-09-01" @default.
• W4387135845 modified "2023-10-18" @default.
• W4387135845 title "#990 Impact on overall survival of crs score in ovarian cancer treated with neoadjuvant chemotherapy" @default.
• W4387135845 doi "https://doi.org/10.1136/ijgc-2023-esgo.684" @default.
• W4387135845 hasPublicationYear "2023" @default.
• W4387135845 type Work @default.
• W4387135845 citedByCount "0" @default.
• W4387135845 crossrefType "proceedings-article" @default.
• W4387135845 hasAuthorship W4387135845A5010610972 @default.
• W4387135845 hasAuthorship W4387135845A5034099505 @default.
• W4387135845 hasAuthorship W4387135845A5038749148 @default.
• W4387135845 hasAuthorship W4387135845A5048878911 @default.
• W4387135845 hasAuthorship W4387135845A5092960937 @default.
• W4387135845 hasAuthorship W4387135845A5092960938 @default.
• W4387135845 hasAuthorship W4387135845A5092960939 @default.
• W4387135845 hasBestOaLocation W43871358451 @default.
• W4387135845 hasConcept C121608353 @default.
• W4387135845 hasConcept C126322002 @default.
• W4387135845 hasConcept C141071460 @default.
• W4387135845 hasConcept C143998085 @default.
• W4387135845 hasConcept C146357865 @default.
• W4387135845 hasConcept C151730666 @default.
• W4387135845 hasConcept C167135981 @default.
• W4387135845 hasConcept C2776694085 @default.
• W4387135845 hasConcept C2777632260 @default.
• W4387135845 hasConcept C2780427987 @default.
• W4387135845 hasConcept C71924100 @default.
• W4387135845 hasConcept C86803240 @default.
• W4387135845 hasConceptScore W4387135845C121608353 @default.
• W4387135845 hasConceptScore W4387135845C126322002 @default.
• W4387135845 hasConceptScore W4387135845C141071460 @default.
• W4387135845 hasConceptScore W4387135845C143998085 @default.
• W4387135845 hasConceptScore W4387135845C146357865 @default.
• W4387135845 hasConceptScore W4387135845C151730666 @default.
• W4387135845 hasConceptScore W4387135845C167135981 @default.
• W4387135845 hasConceptScore W4387135845C2776694085 @default.
• W4387135845 hasConceptScore W4387135845C2777632260 @default.
• W4387135845 hasConceptScore W4387135845C2780427987 @default.
• W4387135845 hasConceptScore W4387135845C71924100 @default.
• W4387135845 hasConceptScore W4387135845C86803240 @default.
• W4387135845 hasLocation W43871358451 @default.
• W4387135845 hasOpenAccess W4387135845 @default.
• W4387135845 hasPrimaryLocation W43871358451 @default.
• W4387135845 hasRelatedWork W167319750 @default.
• W4387135845 hasRelatedWork W1967715255 @default.
• W4387135845 hasRelatedWork W1987468340 @default.
• W4387135845 hasRelatedWork W2047967234 @default.
• W4387135845 hasRelatedWork W2439875401 @default.
• W4387135845 hasRelatedWork W2805900528 @default.
• W4387135845 hasRelatedWork W2908664330 @default.
• W4387135845 hasRelatedWork W3047309708 @default.
• W4387135845 hasRelatedWork W3210326642 @default.
• W4387135845 hasRelatedWork W4220939315 @default.
• W4387135845 isParatext "false" @default.
• W4387135845 isRetracted "false" @default.
• W4387135845 workType "article" @default.